Home  /  Resource Library  /  Durable responses after CD19-targeted CAR-T cell immunotherapy with concurrent ibrutinib for CLL after prior ibrutinib failure

Durable responses after CD19-targeted CAR-T cell immunotherapy with concurrent ibrutinib for CLL after prior ibrutinib failure

ICML 2019: Results of a study investigating CAR T therapy combined with ibrutinib for treatment of relapsed chronic lymphocytic leukemia.